Clinical Trials and Research

This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s (LSE: AZN) Phase III CARDIO-…

AbstractBackgroundCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy associated with conduction disease and arrhythmias, although their true…

AbstractBackgroundCardiac amyloidosis is frequently underdiagnosed and rarer forms (e.g., non-transthyretin or light chain amyloidosis) can be challenging to…

AbstractBACKGROUND:Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded…

Recent research shows that Bayer's investigational PET radiotracer Iodine 124 Evuzamitide meets primary endpoints in Phase III study in patients suspected to…

AbstractObjectivesThe aim of this study was to compare the sensitivity of nerve biopsy, fat aspirate, and skin biopsy in detecting amyloid in symptomatic hereditary…

SummaryAL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect…

AbstractBackgroundAL amyloidosis is a rare systemic disorder related to plasma cell dyscrasias and caused by deposition of monoclonal light chains. Cardiac…

AbstractBackgroundIn patients with suspected amyloid cardiomyopathy (CM) and a monoclonal protein, tissue biopsy is mandatory to exclude amyloid light–chain CM (AL–…

AbstractIntroductionTafamidis is the cornerstone therapy for transthyretin amyloid cardiomyopathy (ATTR–CM); however, validated criteria for monitoring disease…